Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease which is characterized by destruction of cartilage and bone. RA pathogenesis features numerous autoimmune processes such as autoreactive T-cells and the formation of autoantibodies. Amongst the autoantibodies present in RA sera, rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) have emerged as important diagnostic and prognostic markers. However, a considerable number of RA patients do not display RF and/or ACPA. In these cases, the diagnosis of RA relies heavily upon clinical presentation and imaging procedures.
Protagen has focused on identifying novel biomarkers to reliably identify RF/ACPA negative RA using its proprietary SeroTag platform. Based on this research, proprietary biomarker candidates for future diagnostic assay development were discovered.
The first of these markers has entered assay development and is expected to be launched by Q1/2017. Further markers are currently validated and will enter development shortly.